Funding Opportunity PA-18-870 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

Funding Opportunity RFA-AI-18-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between drug resistance mutations present in minority variant viral populations and treatment outcomes, and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

Funding Opportunity PAR-18-869 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Funding Opportunity PAR-18-866 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.

Funding Opportunity RFA-AR-19-012 from the NIH Guide for Grants and Contracts. The NIAMS Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (R61/R33) initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies. We invite research studies aimed at understanding the mechanisms of diseases or conditions relevant to the NIAMS mission, as well as studies aimed at developing or testing diagnostics, therapeutic agents, or preventive interventions up to, but not including, first in human studies. The RISK R61/R33 FOAs are not intended to support clinical trials.

Funding Opportunity PA-18-867 from the NIH Guide for Grants and Contracts. Genome-wide association studies and other disease studies have identified many variants that are statistically associated with disease risk, disease protection, or other traits. However, such studies do not generally show which specific variants in genomic elements cause these effects, or how they result in differences in function. Similarly, genomic sequencing studies in clinical settings have identified many variants in healthy and diseased individuals. However, the pathogenicity of such variants is often unknown, leading to their classification as variants of uncertain significance (VUS), which makes clinical implementation difficult. This Program Announcement and the companion R21 Program Announcement aim to support the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically.

Funding Opportunity PA-18-868 from the NIH Guide for Grants and Contracts. Genome-wide association studies have found many variants associated with disease risk, disease protection, or other traits. However, these studies generally identify many variants that are statistically associated with the trait, but do not show which variants in genomic elements cause these effects, or how they result in differences in function. Similarly, clinical genomic sequencing studies have identified many variants in healthy and diseased individuals, but the pathogenicity of such variants is usually unknown, leading to their classification as variants of uncertain significance (VUSs), which makes clinical implementation difficult. This program aims to support the development of generalizable approaches to study how genetic variants lead to differences in function, how such functional differences lead to disease processes, and how this knowledge can be used clinically.

Notice NOT-NR-18-013 from the NIH Guide for Grants and Contracts

Notice NOT-NR-18-014 from the NIH Guide for Grants and Contracts

Notice NOT-NR-18-015 from the NIH Guide for Grants and Contracts

Notice NOT-CA-18-095 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-037 from the NIH Guide for Grants and Contracts

Notice NOT-MH-18-038 from the NIH Guide for Grants and Contracts

Notice NOT-GM-18-039 from the NIH Guide for Grants and Contracts

Notice NOT-HL-18-639 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-075 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-18-030 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish one or two centers that can rapidly generate high quality whole genome sequence and variant data from a large number of human specimens representing two types of pediatric conditions - childhood cancers and structural birth defects. All sequence data generated under this FOA will be re-processed and harmonized by the Gabriella Miller Kids First Pediatric Data Resource Center (Kids First DRC), which is also charged with building a public-facing, web-based portal that will allow researchers to search, access, aggregate, analyze, and share annotated genomic sequence, variant, and phenotypic datasets. Together these resources will promote comprehensive and cross-cutting research and collaboration within the pediatric research community.

Notice NOT-AG-18-023 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-197 from the NIH Guide for Grants and Contracts

Notice NOT-TR-18-030 from the NIH Guide for Grants and Contracts